- Home
- LFVN vs HURA Comparison
LFVN vs HURA Comparison
Compare LFVN & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LFVN | HURA |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.2M | 131.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LFVN | HURA |
|---|---|---|
| Price | $6.21 | $0.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $35.00 | $12.00 |
| AVG Volume (30 Days) | 193.0K | ★ 662.7K |
| Earning Date | 02-04-2026 | 02-14-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | ★ 143.91 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $228,877,000.00 | N/A |
| Revenue This Year | $1.54 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $7.81 | ★ N/A |
| Revenue Growth | ★ 16.77 | N/A |
| 52 Week Low | $5.69 | $0.70 |
| 52 Week High | $27.38 | $5.50 |
Technical Indicators
Market Signals| Indicator | LFVN | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 25.27 |
| Support Level | $5.80 | $0.72 |
| Resistance Level | $6.41 | $0.80 |
| Average True Range (ATR) | 0.34 | 0.09 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 66.51 | 6.93 |
Price Performance
Historical ComparisonAbout LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.